Litigation

Celgene Corp. v. Biocon Pharma Ltd. et al.

settled
Court
D.N.J.

Patents at issue (2)

Plaintiffs (1)

Summary

Celgene asserted the '800 and '217 patents against Biocon over lenalidomide ANDA products. The case settled.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Record id: 7465800-celgene-corp-v-biocon-pharma-ltd-biocon-ltd-biocon-pharma-inc · edit in Admin